Author: OurCrowd

[Clinch in PR Newswire] Clinch named First Third-Party Ad Serving Solution to Serve Ads to Amazon Custom Audiences, Utilizing a S2S (Server-to-Server) Integration

Oct 23, 2025 |

NEW YORK, Oct. 23, 2025 /PRNewswire/ — Clinch, the Agentic AI platform for omnichannel advertising, today announced an expanded collaboration with Amazon Ads, becoming the first third-party ad serving solution to serve ads to Amazon Custom Audiences, a functionality reserved for creatives served directly by Amazon. Amazon Custom Audiences are custom-built segments that can help brands reach and re-engage with shoppers directly via Amazon DSP. Read more...

Read More

[Alloy Therapeutics in BusinessWire] Alloy Therapeutics announces acquisition of Spannerwerks, a leading provider of drug development consulting services

Oct 23, 2025 |

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceutical companies on the development and launch of new products. Read more...

Read More

[OncoHost in PR Newswire] OncoHost receives New York StatelLaboratory permit, expanding availability of PROphetNSCLC® precision oncology test

Oct 22, 2025 |

BINYAMINA, Israel and CARY, N.C., Oct. 22, 2025 /PRNewswire/ — OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, today announced that it has received a laboratory permit from the New York State Department of Health Wadsworth Center. This permit enables the company to offer its PROphetNSCLC® test to physicians and patients across New York State, marking a key milestone in OncoHost’s U.S. expansion. Read more...

Read More